Rockwell Medical

Rockwell Medical is a publicly traded specialty pharmaceutical and medical device company, not a family office or investment fund. Its shares trade on Nasdaq under the ticker RMTI. It manufactures and sells hemodialysis concentrates directly to dialysis providers.

Following the October 2023 departure of founder and CEO Robert Chioini, chairman Stuart M. Paul assumed principal executive officer duties. The company has not named a permanent CEO as of early 2025. Board composition shifted through activist interventions in 2022 and 2023 (per SEC filings, 2023).

Triferic, an iron-replacement therapy, received FDA approval in 2014 for hemodialysis patients and in 2017 for peritoneal dialysis patients. Despite approval across two delivery mechanisms, the product never achieved meaningful commercial adoption. Rockwell deprioritized Triferic spending following management changes and now derives nearly all revenue from dialysis concentrate sales.

The March 2023 supply agreement transformed Rockwell's sales to DaVita from unpredictable spot orders into committed volume. The contract covers multiple concentrate formulations and represented a majority of Rockwell's total gross revenue within the first year of execution (per the firm's earnings disclosures, 2023–2024).

The US hemodialysis concentrate market is dominated by two in-house manufacturers tied to clinic operators — Fresenius Medical Care and DaVita — and two independent suppliers: Rockwell Medical and Evoqua Water Technologies (now part of Xylem). Rockwell is the only independent supplier of both dry and liquid acid concentrates at commercial scale.

Rockwell Medical trades on Nasdaq under RMTI. Its market capitalization has consistently stayed below $100 million, placing it in the micro-cap segment. The stock has undergone multiple reverse splits and capital raises since the company's 1998 IPO (per SEC filings and public market data).

Rockwell's disclosed operations are US-based. Its single manufacturing facility in Wixom, Michigan, serves its domestic dialysis-clinic customers. The firm has not disclosed any direct international manufacturing or distribution footprint.